Drug Profile
LY 3381916
Alternative Names: LY3381916Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Belgium (PO)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Denmark (PO)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Italy (PO)